Report of the Russian database on adverse drug reactions for COVID-19-related drugs with a focus on favipiravir

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):26-33

​ Mishinova S.A., Syraeva G.I., Kolbin A.S., Polushin Yu.S., Verbiсkaya E.V.
10.36488/cmac.2023.1.26-33
pharmacovigilance COVID-19 favipiravir adverse drug reactions safety signal
Section
Antimicrobials
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):26-33

Objective.

The purpose of this study is to systematize and comprehensively evaluate safety data on the drug favipiravir using the national pharmacovigilance database of the Russian Federation.

Materials and Methods.

The report is based on spontaneous reports in the national automated information system of pharmacovigilance of the Russian Federation for the reporting period from 01.01.2020 – 04.07.2022. To identify safety signals we used disproportionality analysis, to estimate consumption of favipiravir – indicator of the number of consumed DDDs, we additionally performed review of concomitant therapy as a risk factor for serious adverse reactions.

Results.

A total of 412 reports of 585 adverse reactions was included in the analytic phase. The largest number of reports referred to liver and biliary tract disorders – 166 (38%), gastrointestinal disorders – 93 (16%), changes in laboratory and instrumental data – 53 (9%), and immune system disorders – 44 (7%). A total consumption of oral favipiravir expressed in the number of maintenance daily doses for 2021 was 46,417,274.87, i.e. 30 times the consumption of remdesivir and 6 times the consumption of hydroxychloroquine. One potential statistical safety signal such as hypercreatininemia was identified.

Conclusions.

Development of hypercreatininemia is a potential statistical safety signal of favipiravir, which requires further validation.

Sofya А. Mishinova

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia

Gulnara I. Syraeva

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
Research Center Eco-safety, Saint-Petersburg, Russia

Alexey S. Kolbin

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia

Polushin Yu.S.

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia

Verbiсkaya E.V.

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia

  • 1. Kostyleva M.N., Belousov Yu.B., Gracianskaja A.N., Postnikov S.S. Evaluation of safety of drug therapy in clinical practice. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2014;7(1):2732. Russian.
  • 2. Federal Law of Russian Federation №323-FZ of 21 November 2011. «On the fundamentals of protecting the health of citizens of the Russian Federation». Available at: https://base.garant.ru/12174909/. Accessed December 26, 2022. Russian.
  • 3. The World Health Organization (WHO). 2021. Available at: https://apps.who.int/iris/bitstream/handle/10665/43376/9241593830_eng.pdf. Accessed December 26, 2022.
  • 4. Kolbin A.S., Zyrjanov S.K., Belousov D.Ju. Farmakonadzor. Buki Vedi, Izdatel'stvo OKI 2019. 242 р. Russian.
  • 5. Resolution of the government of the Russian Federation, 03.04.2020 N 441 “On the peculiarities of the circulation of medicinal products for medical use, which are intended for use in conditions of the threat of the emergence, occurrence and liquidation of an emergency and for organizing the provision of medical care to persons affected by emergencies, preventing emergencies, preventing and treating diseases that pose a danger to others , diseases and injuries resulting from exposure to adverse chemical, biological, radiation factors.” Available at: https://base.garant.ru/73850814/. Accessed December 26, 2022. Russian.
  • 6. ClinicalTrials.gov. Available at: www.clinicaltrials.gov/ct2/show/study/NCT04542694?recrs=e&rslt=With&type=Intr&cond=favipiravir&draw=2&rank=4. Accessed December 26, 2022.
  • 7. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):11921198. DOI: 10.1016/j.eng.2020.03.007
  • 8. Chen C., Zhang Y., Huang J., Yin P., Cheng Z., Wu J., et al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial. Front Pharmacol. 2021;12:683296. DOI: 10.3389/fphar.2021.683296
  • 9. State register of pharmaceutical products for medical purposes. Available at: https://grls.rosminzdrav.ru. Accessed December 26, 2022. Russian.
  • 10. Instructions for the medical use of the drug Avifavir. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cea6f2a4-8001-4b02-a418-e992fd3138c1. December 26, 2022. Russian.
  • 11. Gholami K., Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother. 1999;33(2):236-240. DOI: 10.1345/aph.17440
  • 12. Medical dictionary for regulatory activities (MedDRA). Available at: https://www.meddra.org/how-to-use/support-documentation/russian. Accessed December 26, 2022.
  • 13. European Medicines Agency: guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products 2014. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf. Accessed December 26, 2022.
  • 14. Bate A., Lindquist M., Edwards I.R., Olsson S., Orre R., Lansner A., et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-321. DOI: 10.1007/s002280050466
  • 15. Evans S.J., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483-486. DOI: 10.1002/pds.677
  • 16. Bate A., Lindquist M., Edwards I.R., Olsson S., Orre R., Lansner A., et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-321. DOI: 10.1007/s002280050466
  • 17. Duggirala H.J., Tonning J.M., Smith E., Bright R.A., Baker J.D., Ball R., et al. Use of data mining at the Food and Drug Administration. J Am Med Inform Assoc. 2016;23(2):428-434. DOI: 10.1093/jamia/ocv063
  • 18. EudraVigilance expert working group (EV-EWG). Screening for adverse reactions in EudraVigilance. EMA/849944/2016. EMA; 2016. Available at: www.ema.europa.eu/en/documents/other/screening-adversereactions-eudravigilance_en.pdf. Accessed December 26, 2022.
  • 19. Аutomated information system of Roszdravnadzor. Available at: http://external.roszdravnadzor.ru/?type=logon. Accessed December 26, 2022. Russian.
  • 20. Guidelines for ATC classification and DDD assignment, 2023. Available at: www.whocc.no/filearchive/publications/2023_guidelines_web.pdf. Accessed December 26, 2022.
  • 21. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. Available at: www.whocc.no/atc_ddd_index/?code=J05AX27/. Accessed December 26, 2022.
  • 22. Zhuravleva E.O., Velts N.Yu., Kutekhova G.V., Darmostukova M.A., Alyautdin R.N. Signal as a tool of the pharmacovigilance. Safety and risk of pharmacotherapy. 2018;6(2):61-67. Russian. DOI: 10.30895/2312-7821-20186-2-61-67
  • 23. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. DOI: 10.1038/s41422-0200282-0
  • 24. Borobia A.M., Mora-Rillo M., Ramírez Olivencia G., Lago M., Arsuaga M., De la Calleet F., et al. High dose favipiravir: first experience in a patient with Ebola. Clin Ther. 2015;37(8):e15. DOI: 10.1016/j.clinthera.2015.05.054
  • 25. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45-51. DOI: 10.1016/S2055-6640(20)30016-9
  • 26. Kaur R.J., Charan J., Dutta S., Sharma P., Bhardwaj P., Sharma Pr., et al. Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infect Drug Resist. 2020;13:4427-4438. DOI: 10.2147/IDR.S287934
  • 27. Bezin J., Bosco-Levy P., Pariente A. False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie. 2017;72(4):415-420. DOI: 10.1016/j.therap.2016.09.020
  • 28. Zalolochina K.E., Ushkalova E.A., Kazakov A.S., Zyryanov S.K., Polivanov V.A. Analysis of adverse reactions in elderly patients based on quantitative methods of signal detection. Safety and risk of pharmacotherapy. 2021;9(3):144-153. Russian. DOI: 10.30895/23127821-2021-9-3-144-153
Views
0 Abstract
0 PDF
0 Crossref citations
Shared